Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up

[1] Witjes JA(2020)European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines Eur Urol 49 466-475

[2] Bruins HM(2006)Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 76 639-657

[3] Cathomas R(2019)European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update Eur Urol 61 109-118

[4] Compérat EM(2003)Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses Urology 33 66.e25-31

[5] Cowan NC(2015)Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer Urol Oncol 121 29-37

[6] Gakis G(2018)Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance BJU Int 64 846-854

[7] Sylvester RJ(2013)Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data Eur Urol 66 253-262

[8] van der Meijden AP(2019)The global burden of urinary bladder cancer: an update World J Urol 199 655-662

[9] Oosterlinck W(2014)The economics of bladder cancer: costs and considerations of caring for this disease Eur Urol 75 853-860

[10] Witjes JA(2018)Development of a 90-minute integrated noninvasive urinary assay for bladder cancer detection J Urol 70 106-119

[1] Witjes JA(2020)European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines Eur Urol 49 466-475

[2] Bruins HM(2006)Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 76 639-657

[3] Cathomas R(2019)European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update Eur Urol 61 109-118

[4] Compérat EM(2003)Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses Urology 33 66.e25-31

[5] Cowan NC(2015)Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer Urol Oncol 121 29-37

[6] Gakis G(2018)Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance BJU Int 64 846-854

[7] Sylvester RJ(2013)Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data Eur Urol 66 253-262

[8] van der Meijden AP(2019)The global burden of urinary bladder cancer: an update World J Urol 199 655-662

[9] Oosterlinck W(2014)The economics of bladder cancer: costs and considerations of caring for this disease Eur Urol 75 853-860

[10] Witjes JA(2018)Development of a 90-minute integrated noninvasive urinary assay for bladder cancer detection J Urol 70 106-119